The epidermal growth factor receptor (EGFR) inhibitor erlotinib, a key drug in the clinical treatment of small cell lung cancer [80], was found to have an off-target effect in activating mitochondrial metabolic function in non-small cell lung cancer [78]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.